A new oral hypoglycaemic drug, dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), was confirmed to reduce the risk of cardiovascular adverse events (AEs) and improve coronary heart disease and HF outcomes in multiple clinical trials.8 At present, dapagliflozin has been extensively used for type 2 diabetes mellitus (T2DM) and HF. Here, SLC5A2 is linked to type 2 diabetes mellitus.